(4-Bromo-2-fluorophenyl)[4-(3,5-dimethylpyridin-2-yl)piperazin-1-yl]methanone → HCID 71252136, Verbindung

HRID 2411389Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 2411389
[CH2:1]([C@@H:3]1[CH2:7][CH2:6][S:5](=[O:9])(=[O:8])[NH:4]1)[CH3:2].Br[C:11]1[CH:16]=[CH:15][C:14]([C:17]([N:19]2[CH2:24][CH2:23][N:22]([C:25]3[C:30]([CH3:31])=[CH:29][C:28]([CH3:32])=[CH:27][N:26]=3)[CH2:21][CH2:20]2)=[O:18])=[C:13]([F:33])[CH:12]=1>>[CH3:31][C:30]1[C:25]([N:22]2[CH2:23][CH2:24][N:19]([C:17]([C:14]3[CH:15]=[CH:16][C:11]([N:4]4[C@H:3]([CH2:1][CH3:2])[CH2:7][CH2:6][S:5]4(=[O:9])=[O:8])=[CH:12][C:13]=3[F:33])=[O:18])[CH2:20][CH2:21]2)=[N:26][CH:27]=[C:28]([CH3:32])[CH:29]=1

Komponenten

3

Edukt 2

HCID 58484626(4-Bromo-2-fluorophenyl)[4-(3,5-dimethylpyridin-2-yl)piperazin-1-yl]methanoneHCID 86676750HCID 86676750, Verbindung

Produkt 1

HCID 71252136HCID 71252136, VerbindungAusbeute 13 %

Versuchsvorschrift

Using (R)-3-ethylisothiazolidine 1,1-dioxide (150 mg) described in Preparation Example 3 and (4-bromo-2-fluorophenyl)[4-(3,5-dimethylpyridin-2-yl)piperazin-1-yl]methanone (439 mg) described in Preparation Example 114 and by the reaction and treatment in the same manner as in Example 1, the title compound (60 mg) was obtained.

Aufarbeitung

  1. customdescribed in Preparation Example 114 and by the reaction and treatment in the same manner as in Example 1

Quellen und Nachweise

ORD-Eintrag
ord-450d8d2d71104b21a85325d289006274
Quelldatensatz
uspto-grants-2014_08
Patentnummer
US08816079B2

Notizen zur Reaktion

Wird geladen…